Tumor Marker Screening

For more information or to consult a doctor, please contact the staff.

Office: 098-273-0437
E-mail : [email protected]
Line ID : @vaanaaclinic

Category:
Description

Blood test for cancer markers It is a condition in which cells grow abnormally in which the proliferation mechanism of the cell is lost and the genetic material inside the cell changes abnormally. causing it to grow into a mass of malignant tumors Cancer cells naturally produce cancer markers that are released into the bloodstream.  Each of these markers has a different relationship to the organ of cancer. Quantitative detection of cancer markersIt is a method used for screening in conjunction with other diagnoses by doctors. It is also used to follow up with the doctor’s treatment results.

Cancer is a common fear of people. Because most people know that they have this disease. When the symptoms of the disease appear, it is too difficult to treat. But if we know from the early stages, it will increase the chances of curing cancer easily.

Indicators associated with cancer cells in various organs.

  • CA19-9 is associated with cancers of the colon, pancreas, liver, stomach.
  • AFP is associated with cancers of the liver, stomach, pancreas, testis.
  • CEA is associated with cancers of the stomach, colon, pancreas, lung and liver.
  • HCG is associated with cancers of the ovaries, liver, lung, stomach, rectum.
  • HGH is associated with lung cancer.
  • CA 153 is associated with cancers of the breast, ovum, liver, lung, stomach, rectum.
  • f-PSA is associated with cancers of the prostate, endometrium, liver, lung, pancreas, breast.
  • PSA is associated with cancers of the prostate, endometrium, liver, lung, pancreas, and breast.
  • NSE is associated with cancers of the lung, pancreas, thyroid.
  • CA 125 is associated with cancers of the ovaries, liver, stomach, pancreas, breast, uterus.
  • Ferritin is associated with cancers of the liver, breast, lung, pancreas.
Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Tumor Marker Screening”